Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2021 Earnings Conference Call July 29, 2021 6:00 PM ET Â Company Participants Edward Chung - Head of IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andrew Last - EVP and COO Annette Tumolo - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Brandon Couillard - Jefferies Dan Leonard - Wells Fargo Jack Meehan - Nephron Research Operator Good afternoon, ladies and gentlemen, and wel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2021 Earnings Conference Call April 29, 2021 6:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Annette Tumolo - EVP & President, Life Science Group Dara Wright - EVP & President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Daniel Leonard - Wells Fargo Securities Patrick Donnelly - Citigroup Nisarg Shah - Nephron Operator L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIOb New York Stock Exchange ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2020 Earnings Conference Call February 11, 2021 6:00 PM ET Corporate Participants Ron Hutton - Treasurer Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chief Financial Officer Andy Last - Executive Vice President and Chief Operating Officer Annette Tumolo - President of the Life Science Group Dara Wright - President of the Clinical Diagnostics Group Conference Call Participants Dan Leonard - Wells Fargo Brandon Couillard - Jeffer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIOb New York Stock Exchange ☐ TRANSITION REPORT PURSUANT TO SECTION ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2020 Earnings Conference Call October 29, 2020 6:00 PM ET Company Participants Kevin Han - IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Annette Tumolo - EVP & President, Life Science Group Conference Call Participants Patrick Donnelly - Citigroup Brandon Couillard - Jefferies Dan Leonard - Wells Fargo Securities Jack Meehan - Nephron Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2020 Earnings Conference Call July 30, 2020 6:00 PM ET Company Participants Kevin Han - Senior Director, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chief Financial Officer Andy Last - Executive Vice President and Chief Operating Officer Annette Tumolo - President of Life Science Group Dara Wright - President of the Clinical Diagnostics Group Conference Call Participants Dan Leonard - Wells Fargo Patrick Don ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...